Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
Mitsuyoshi Takahara,1 Toshihiko Shiraiwa,2 Taka-aki Matsuoka,3 Kaoru Yamamoto,2 Yoshifumi Maeno,2 Yuka Shiraiwa,2 Yoko Yoshida,2 Naoto Katakami,4 Hiroaki Iijima,5 Hideyuki Katsumata,6 Kenji Arakawa,5 Toshio Hashimoto,5 Iichiro Shimomura3 1Department of Diabetes Care Medicine, Osaka University Gradua...
Guardado en:
Autores principales: | Takahara M, Shiraiwa T, Matsuoka TA, Yamamoto K, Maeno Y, Shiraiwa Y, Yoshida Y, Katakami N, Iijima H, Katsumata H, Arakawa K, Hashimoto T, Shimomura I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/83540f3531f743f581e795fb20d708de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018) -
Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019) -
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021) -
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017) -
Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
por: Nina A. Petunina, et al.
Publicado: (2016)